Investments
195Portfolio Exits
27Funds
19About Sanderling Ventures
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs.
Sanderling Ventures Headquarter Location
400 S. El Camino Real Suite 1200
San Mateo, California, 94402,
United States
650-401-2000
Latest Sanderling Ventures News
Jun 19, 2021
ViaCyte , a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures. The company intends to use the funds to advance its portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. Led by Michael Yang, President and Chief Executive Officer, and Brittany Bradrick, Chief Financial Officer and Chief Operating Officer, ViaCyte is a regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. The company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with such companies as CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California.
Sanderling Ventures Investments
195 Investments
Sanderling Ventures has made 195 investments. Their latest investment was in Trefoil Therapeutics as part of their Series A - III on March 3, 2022.
Sanderling Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/22/2022 | Series A - III | Trefoil Therapeutics | $11.97M | Yes | 1 | |
6/23/2021 | Series B - II | Glycomine | $35M | No | 12 | |
6/9/2021 | Series D - IV | ViaCyte | $45M | No | 14 | |
3/12/2021 | Series D | |||||
5/27/2020 | Unattributed VC |
Date | 3/22/2022 | 6/23/2021 | 6/9/2021 | 3/12/2021 | 5/27/2020 |
---|---|---|---|---|---|
Round | Series A - III | Series B - II | Series D - IV | Series D | Unattributed VC |
Company | Trefoil Therapeutics | Glycomine | ViaCyte | ||
Amount | $11.97M | $35M | $45M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 1 | 12 | 14 |
Sanderling Ventures Portfolio Exits
27 Portfolio Exits
Sanderling Ventures has 27 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/11/2022 | Acquired | 9 | |||
8/24/2020 | Acquired | 4 | |||
6/27/2017 | Acquired | 4 | |||
Date | 7/11/2022 | 8/24/2020 | 6/27/2017 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 9 | 4 | 4 |
Sanderling Ventures Acquisitions
1 Acquisition
Sanderling Ventures acquired 1 company. Their latest acquisition was Pacira Biosciences on March 05, 2007.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
3/5/2007 | Debt | $111.25M | Acq - Fin |
Date | 3/5/2007 |
---|---|
Investment Stage | Debt |
Companies | |
Valuation | |
Total Funding | $111.25M |
Note | Acq - Fin |
Sources |
Sanderling Ventures Fund History
19 Fund Histories
Sanderling Ventures has 19 funds, including Sanderling I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/30/2008 | Sanderling I | Early-Stage Venture Capital | Closed | $7M | 1 |
5/1/2005 | Sanderling Beteiligungs | Co-Investment Fund | Closed | $7M | 1 |
5/1/2005 | Sanderling VI LP | Early-Stage Venture Capital | Closed | $223M | 1 |
5/1/2005 | Sanderling Limited VI | ||||
5/1/2004 | Sanderling VI Co-Investment LP |
Closing Date | 4/30/2008 | 5/1/2005 | 5/1/2005 | 5/1/2005 | 5/1/2004 |
---|---|---|---|---|---|
Fund | Sanderling I | Sanderling Beteiligungs | Sanderling VI LP | Sanderling Limited VI | Sanderling VI Co-Investment LP |
Fund Type | Early-Stage Venture Capital | Co-Investment Fund | Early-Stage Venture Capital | ||
Status | Closed | Closed | Closed | ||
Amount | $7M | $7M | $223M | ||
Sources | 1 | 1 | 1 |
Sanderling Ventures Team
14 Team Members
Sanderling Ventures has 14 team members, including current Managing Director, Robert McNeil.
Name | Work History | Title | Status |
---|---|---|---|
Robert McNeil | Managing Director | Current | |
Fred A. Middleton | Managing Director | Current | |
Timothy Mills PhD | Sotera Wireless, Torax Medical, NeoMend, Target Therapeutics, Baxter International, UC Irvine Medical Center, and University of California, San Francisco | Managing Director | Current |
Timothy Wollaeger | Managing Director | Current | |
Donald D Huffman | Chief Financial Officer | Former |
Name | Robert McNeil | Fred A. Middleton | Timothy Mills PhD | Timothy Wollaeger | Donald D Huffman |
---|---|---|---|---|---|
Work History | Sotera Wireless, Torax Medical, NeoMend, Target Therapeutics, Baxter International, UC Irvine Medical Center, and University of California, San Francisco | ||||
Title | Managing Director | Managing Director | Managing Director | Managing Director | Chief Financial Officer |
Status | Current | Current | Current | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.